Sangamo Therapeutics Stock Probability Of Bankruptcy
SGMO Stock | USD 0.62 0.02 3.33% |
Sangamo | Probability Of Bankruptcy |
Sangamo Probability Of Bankruptcy Analysis
Sangamo Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 110.7M | 111.3M | 154.0M | 161.7M | Total Revenue | 110.7M | 111.3M | 176.2M | 185.0M |
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Sangamo Therapeutics Probability Of Bankruptcy | Over 74% |
Most of Sangamo Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangamo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Sangamo Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Sangamo Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Sangamo Therapeutics financial health.
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sangamo Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Sangamo Therapeutics is extremely important. It helps to project a fair market value of Sangamo Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Sangamo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sangamo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sangamo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition |
Based on the latest financial disclosure, Sangamo Therapeutics has a Probability Of Bankruptcy of 74%. This is 70.94% higher than that of the Biotechnology sector and 34.94% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 85.79% lower than that of the firm.
Sangamo Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangamo Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sangamo Therapeutics could also be used in its relative valuation, which is a method of valuing Sangamo Therapeutics by comparing valuation metrics of similar companies.Sangamo Therapeutics is currently under evaluation in probability of bankruptcy category among related companies.
Sangamo Therapeutics Main Bankruptcy Drivers
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Net Debt | (36.0M) | (89.2M) | (130.8M) | (57.3M) | (7.1M) | (7.5M) | |
Total Current Liabilities | 69.9M | 143.5M | 127.9M | 111.7M | 47.7M | 34.0M | |
Non Current Liabilities Total | 134.9M | 297.6M | 218.7M | 155.8M | 34.7M | 57.7M | |
Total Assets | 637.5M | 938.6M | 721.9M | 562.5M | 165.3M | 218.1M | |
Total Current Assets | 405.5M | 659.7M | 398.8M | 300.3M | 94.3M | 175.7M | |
Total Cash From Operating Activities | (144.4M) | 169.9M | (233.3M) | (223.6M) | (224.8M) | (213.6M) |
Sangamo Fundamentals
Return On Equity | -1.36 | ||||
Return On Asset | -0.18 | ||||
Profit Margin | (1.46) % | ||||
Operating Margin | (24.76) % | ||||
Current Valuation | 84.33 M | ||||
Shares Outstanding | 203.67 M | ||||
Shares Owned By Insiders | 9.40 % | ||||
Shares Owned By Institutions | 43.79 % | ||||
Number Of Shares Shorted | 10.88 M | ||||
Price To Earning | (15.31) X | ||||
Price To Book | 1.53 X | ||||
Price To Sales | 0.72 X | ||||
Revenue | 176.23 M | ||||
Gross Profit | (138.6 M) | ||||
EBITDA | (92.1 M) | ||||
Net Income | (257.83 M) | ||||
Cash And Equivalents | 315.72 M | ||||
Cash Per Share | 2.02 X | ||||
Total Debt | 38.1 M | ||||
Debt To Equity | 0.13 % | ||||
Current Ratio | 2.86 X | ||||
Book Value Per Share | 0.47 X | ||||
Cash Flow From Operations | (224.84 M) | ||||
Short Ratio | 3.03 X | ||||
Earnings Per Share | (1.48) X | ||||
Target Price | 3.5 | ||||
Number Of Employees | 405 | ||||
Beta | 1.44 | ||||
Market Capitalization | 127.23 M | ||||
Total Asset | 165.32 M | ||||
Retained Earnings | (1.41 B) | ||||
Working Capital | 46.6 M | ||||
Current Asset | 212.58 M | ||||
Current Liabilities | 20.1 M | ||||
Z Score | -10.34 | ||||
Net Asset | 165.32 M |
About Sangamo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangamo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangamo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangamo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California. Sangamo Therapeutics is traded on NASDAQ Exchange in the United States.
Currently Active Assets on Macroaxis
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:Check out Sangamo Therapeutics Piotroski F Score and Sangamo Therapeutics Altman Z Score analysis. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.